These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11516363)

  • 1. The metabolic toxicities of antiretroviral therapy.
    Herman JS; Easterbrook PJ
    Int J STD AIDS; 2001 Sep; 12(9):555-62; quiz 563-4. PubMed ID: 11516363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic disturbances associated with HAART].
    Olczak A
    Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection.
    Heath KV; Montaner JS; Bondy G; Singer J; O'Shaughnessy MV; Hogg RS
    Curr Drug Targets; 2003 Jan; 4(1):13-22. PubMed ID: 12528986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities.
    Moyle G; Carr A
    HIV Clin Trials; 2002; 3(1):89-98. PubMed ID: 11894812
    [No Abstract]   [Full Text] [Related]  

  • 5. Older HIV patients face metabolic complications.
    Greene MD
    Nurse Pract; 2003 Jun; 28(6):17-25; quiz 26-7. PubMed ID: 12796620
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolic complications of antiretroviral therapy in children.
    Leonard EG; McComsey GA
    Pediatr Infect Dis J; 2003 Jan; 22(1):77-84. PubMed ID: 12544413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
    Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults.
    Monier PL; Wilcox R
    Am J Med Sci; 2004 Jul; 328(1):48-56. PubMed ID: 15254441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.
    Worm D; Kirk O; Andersen O; Vinten J; Gerstoft J; Katzenstein TL; Nielsen H; Pedersen C
    HIV Med; 2002 Oct; 3(4):239-46. PubMed ID: 12444941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Side effects of antiretroviral therapy].
    Teodor A; Teodor D; Luca V
    Rev Med Chir Soc Med Nat Iasi; 2004; 108(1):23-6. PubMed ID: 15688751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
    Holstein A; Plaschke A; Egberts EH
    Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolic disorders and lipodystrophy. Adverse effects of antiretroviral therapy].
    Goebel FD; Westner I
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():40-4. PubMed ID: 11373778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
    Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
    Carr A; Miller J; Eisman JA; Cooper DA
    AIDS; 2001 Apr; 15(6):703-9. PubMed ID: 11371684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.
    Barbaro G
    Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction?
    Walker UA; Brinkman K
    HIV Med; 2001 Jul; 2(3):163-5. PubMed ID: 11737396
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.